Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Lymphoma

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 31 articles: HTML format

Single Articles

December 2022
1. DICKINSON MJ, Carlo-Stella C, Morschhauser F, Bachy E, et al
   Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
   N Engl J Med. 2022;387:2220-2231.
   PubMed     Abstract available
   
   
   
2. BARTLETT NL
   Bispecific Antibodies in Lymphoma - Another Win for T Cells.
   N Engl J Med. 2022;387:2285-2286.
   PubMed    
   
   
   November 2022
3. ROSCHEWSKI M, Bollard CM
   Are We Too Reliant on Radiation Therapy for Children with Hodgkin's Lymphoma?
   N Engl J Med. 2022;387:1710-1712.
   PubMed    
   
   
   
4. CASTELLINO SM, Pei Q, Parsons SK, Hodgson D, et al
   Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
   N Engl J Med. 2022;387:1649-1660.
   PubMed     Abstract available
   
   
   October 2022
5. ANSELL SM, Radford J, Straus DJ
   Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply.
   N Engl J Med. 2022;387:1527-1528.
   PubMed    
   
   
   
6. HASLAM A, Prasad V
   Brentuximab Vedotin in Advanced Hodgkin's Lymphoma.
   N Engl J Med. 2022;387:1527.
   PubMed    
   
   
   September 2022
7. WANG ML, Le Gouill S, Dreyling M
   Treatment of Mantle-Cell Lymphoma. Reply.
   N Engl J Med. 2022;387:1148.
   PubMed    
   
   
   
8. ESKAZAN AE
   Treatment of Mantle-Cell Lymphoma.
   N Engl J Med. 2022;387:1147-1148.
   PubMed    
   
   
   
9. FERHANOGLU B, Birtas Atesoglu E, Ozbalak M
   Treatment of Mantle-Cell Lymphoma.
   N Engl J Med. 2022;387:1147.
   PubMed    
   
   
   
10. CLIFF ERS, Dickinson M
    Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1146-1147.
    PubMed    
    
    
    
11. ROSCHEWSKI M, Staudt LM, Wilson WH
    Burkitt's Lymphoma.
    N Engl J Med. 2022;387:1111-1122.
    PubMed    
    
    
    
12. ARMITAGE JO, Longo DL
    Mantle-Cell Lymphoma. Reply.
    N Engl J Med. 2022;387:1050.
    PubMed    
    
    
    
13. YAVORKOVSKY LL
    Mantle-Cell Lymphoma.
    N Engl J Med. 2022;387:1049.
    PubMed    
    
    
    July 2022
14. ANSELL SM, Radford J, Connors JM, Dlugosz-Danecka M, et al
    Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
    N Engl J Med. 2022 Jul 13. doi: 10.1056/NEJMoa2206125.
    PubMed     Abstract available
    
    
    
15. LONGO DL, Armitage JO
    A Better Treatment for Advanced-Stage Hodgkin's Lymphoma?
    N Engl J Med. 2022 Jul 13. doi: 10.1056/NEJMe2207639.
    PubMed    
    
    
    June 2022
16. ARMITAGE JO, Longo DL
    Mantle-Cell Lymphoma.
    N Engl J Med. 2022;386:2495-2506.
    PubMed    
    
    
    
17. WANG ML, Jurczak W, Jerkeman M, Trotman J, et al
    Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2201817.
    PubMed     Abstract available
    
    
    May 2022
18. BERTONI F, Rossi D, Zucca E
    Marginal-Zone Lymphomas. Reply.
    N Engl J Med. 2022;386:1962-1963.
    PubMed    
    
    
    
19. HENRY B, Buffet P, Bates I
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:1962.
    PubMed    
    
    
    
20. MATUCHANSKY C
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:1962.
    PubMed    
    
    
    March 2022
21. FORST DA, Restrepo JA, Gonzalez RG, Jones PS, et al
    Case 7-2022: A 65-Year-Old Woman with Depression, Recurrent Falls, and Inability to Care for Herself.
    N Engl J Med. 2022;386:977-986.
    PubMed    
    
    
    February 2022
22. ROSSI D, Bertoni F, Zucca E
    Marginal-Zone Lymphomas.
    N Engl J Med. 2022;386:568-581.
    PubMed    
    
    
    January 2022
23. SPANJAART AM, van der Valk FM, van Rooijen G, Brouwer MC, et al
    Confused about Confusion.
    N Engl J Med. 2022;386:80-87.
    PubMed    
    
    
    December 2021
24. TILLY H, Morschhauser F, Sehn LH, Friedberg JW, et al
    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2115304.
    PubMed     Abstract available
    
    
    
25. BISHOP MR, Dickinson M, Purtill D, Barba P, et al
    Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMoa2116596.
    PubMed     Abstract available
    
    
    
26. ROSCHEWSKI M, Longo DL, Wilson WH
    CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?
    N Engl J Med. 2021 Dec 14. doi: 10.1056/NEJMe2118899.
    PubMed    
    
    
    
27. LOCKE FL, Miklos DB, Jacobson CA, Perales MA, et al
    Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
    N Engl J Med. 2021 Dec 11. doi: 10.1056/NEJMoa2116133.
    PubMed     Abstract available
    
    
    September 2021
28. STOKKE JL, Szymanski LJ, Bankamp B, Pratt F, et al
    MMR Vaccine-Associated Disseminated Measles in an Immunocompromised Adolescent.
    N Engl J Med. 2021;385:1246-1248.
    PubMed    
    
    
    
29. LYU X, Guan X
    Gingival Ulceration.
    N Engl J Med. 2021;385:e33.
    PubMed    
    
    
    June 2021
30. SEHN LH, Salles G
    Diffuse Large B-Cell Lymphoma. Reply.
    N Engl J Med. 2021;384:2262.
    PubMed    
    
    
    
31. LANG R, Gill MJ
    Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2021;384:2261-2262.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: